OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.60
+0.56 (+9.27%)
At close: 4:00PM EDT

6.57 -0.03 (-0.45%)
After hours: 4:09PM EDT

Stock chart is not supported by your current browser
Previous Close6.04
Open6.03
Bid0.00 x 1300
Ask0.00 x 900
Day's Range5.91 - 6.82
52 Week Range5.20 - 12.44
Volume160,612
Avg. Volume81,713
Market Cap162.571M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Trade prices are not sourced from all markets
  • GlobeNewswire24 days ago

    Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports that the first patient has been randomized to receive either OV935 or placebo in the ELEKTRA trial and that patient screening is underway for the ARCADE trial.

  • GlobeNewswire29 days ago

    Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018

    NEW YORK, Sept. 19, 2018-- Ovid Therapeutics Inc., a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that ...

  • OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?
    Zackslast month

    OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?

    OVID THERAPEUTC has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswirelast month

    Dr. Yaron Werber, Chief Business and Financial Officer, to Return to Wall Street

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Yaron Werber, M.D., chief business and financial officer, will leave the company effective Friday, September 21, 2018. Dr. Werber joined Ovid as chief financial officer in June 2015 after nearly 15 years of experience as a highly-ranked biotechnology research analyst at marquee Wall Street firms.

  • GlobeNewswire2 months ago

    Ovid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018

    The conference will be held at the InterContinential New York Barclay Hotel. The company will give a corporate presentation on Friday, September 7, 2018 at 11:00 a.m. ET. Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Announces Phase 2 STARS Topline Data Accepted for Presentation at American Academy of Child And Adolescent Psychiatry Annual Meeting

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that an abstract on OV101 was accepted for poster presentation at the 65th American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting taking place in Seattle, Wash., October 22 to 27, 2018. AACAP is the largest international gathering of child and adolescent psychiatrists.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the second quarter ended June 30, 2018 and provided an overview of the company’s recent clinical progress. “Earlier this week we announced positive topline data from the Phase 2 STARS trial in Angelman syndrome, the first industry-sponsored, randomized, double-blind, placebo-controlled study with a hierarchy of prespecified endpoints,” said Jeremy Levin, DPhil, MB, BChir, chairman and chief executive officer of Ovid Therapeutics. Importantly, CGI-I was the first measure on the prespecified endpoint analysis in the STARS trial.

  • GlobeNewswire2 months ago

    Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome

    Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the Phase 2 STARS trial of OV101 achieved its primary endpoint of safety and tolerability. The investigational medicine showed a favorable safety profile and was well tolerated in adults and adolescents with Angelman syndrome.

  • ACCESSWIRE6 months ago

    Wired News – Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation

    LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Axsome Therapeutics, Inc. (NASDAQ: AXSM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXSM as the Company's latest news hit the wire. On April 23, 2018, the Company announced that it has enrolled first patient into a Phase-2 trial assessing AXS-05 for smoking cessation treatment.

  • ACCESSWIRE6 months ago

    Wired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas

    Stock Monitor: Ovid Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Clementia Pharma Inc. (NASDAQ: CMTA ...